Preparation of bovine viral diarrhea disease virus 1 virus-like particles and evaluation of its immunogenicity in a guinea pig model.
- Author:
Shandian GAO
1
;
Zhonghui ZHANG
1
;
Zhancheng TIAN
1
;
Jinming WANG
1
;
Junzheng DU
1
;
Guiquan GUAN
1
;
Hong YIN
1
Author Information
- Publication Type:Journal Article
- Keywords: baculovirus; bovine viral diarrhea virus; immunogenicity; virus-like particles
- MeSH: Animals; Antibodies, Viral; Diarrhea; Diarrhea Virus 1, Bovine Viral; Guinea Pigs; Mineral Oil; Viral Envelope Proteins; Viral Vaccines
- From: Chinese Journal of Biotechnology 2022;38(1):130-138
- CountryChina
- Language:Chinese
- Abstract: In order to obtain virus-like particles (VLPs) for prevention of bovine viral diarrhea virus 1 (BVDV-1), the C-Erns-E1-E2 region was cloned into a pFastBacDaul vector for generating the recombinant Bacmid-BVDV-1 in DH10Bac Escherichia coli. The recombinant baculovirus Baculo-BVDV-1 was produced by transfecting the Sf9 cells with Bacmid-BVDV-1. The expressed protein and the assembled VLPs were determined by immunofluorescence, Western blotting and electron microscopy. Guinea pigs were immunized with inactivated VLPs coupled with the Montanide ISA-201 adjuvant. The immunogenicity of VLPs was evaluated by monitoring the humoral immune response with neutralizing antibody titer determination, as well as by analyzing the cell-mediated immune response with lymphocyte proliferation assay. The protective efficacy of VLPs was evaluated by challenging with 106 TCID50 virulent BVDV-1 strain AV69. The results showed that the recombinant Baculo-BVDV-1 efficiently expressed BVDV structural protein and form VLPs in infected Sf9 cells. The immunization of guinea pigs with VLPs resulted in a high titer (1:144) of neutralizing antibody, indicating an activated cellular immunity. Significantly lower viral RNA in the blood of the post-challenged immunized guinea pigs was observed. The successful preparation of BVDV VLPs with insect cell expression system and the observation of the associated immunogenicity may facilitate further development of a VLPs-based vaccine against BVD.
